BILL ANALYSIS

HR6624

NEUTRAL

Biological Intellectual Property Protection Act of 2025

HR6624 (Biological Intellectual Property Protection Act of 2025) has been assessed with a neutral outlook for investors. This legislation directly affects Amgen ($AMGN), $DNA, Regeneron ($REGN) and $TWST. The primary sectors impacted are Technology, Healthcare and Manufacturing. View the full bill text on Congress.gov.

neutral

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR6624 forces onshoring of synthetic biology IP and manufacturing away from PRC entities; no direct spending, but massive supply chain restructuring

Domestic pure-plays $DNA (Ginkgo Bioworks) and $TWST (Twist Bioscience) are direct structural beneficiaries

Large biopharma $AMGN and $REGN face near-term capex pressure but gain long-term IP protection; neutral with downside risk on execution

Bipartisan support and a Senate companion bill increase passage probability; floor vote likely within weeks

How HR6624 Affects the Market

The bill is a catalyst for the U.S. synthetic biology sector. $DNA at $8.07 with a 30-day gain of 31.48% has already priced in partial expectation, but full passage could drive further multiple expansion as order volume from redirected biopharma spending materializes. $AMGN at $348.89 and $REGN at $706.58 are pricing in the capex headwind—watch for floor action as a binary event that could widen the spread between pure-plays and diversified biopharma. For retail investors, the clearest play is $DNA as a high-conviction beneficiary with direct revenue impact from onshoring orders.

Bill Details

Metric	Value
Bill Number	HR6624
Market Sentiment	neutral
Event Date	April 22, 2026
Affected Sectors	Technology, Healthcare, Manufacturing
Affected Stocks	Amgen ($AMGN), $DNA, Regeneron ($REGN), $TWST
Source	View on Congress.gov →

Summary

HR6624 forces a structural onshoring of U.S. synthetic biology IP and manufacturing away from PRC entities. Domestic pure-plays Ginkgo Bioworks ($DNA) and Twist Bioscience ($TWST) are direct beneficiaries, while large biopharma Amgen ($AMGN) and Regeneron ($REGN) face near-term capex pressure but reduced long-term IP risk. The bill advanced out of committee with bipartisan support and has an identical Senate companion bill, increasing passage probability.

Full AI Market Analysis

On April 22, 2026, the House Foreign Affairs Committee ordered HR6624, the Biological Intellectual Property Protection Act of 2025, reported out on a 30-14 vote. The bill, sponsored by Rep. Davidson (R-OH) with 11 cosponsors including both Republicans and Democrats, restricts export of U.S. synthetic biology intellectual property and sensitive information to PRC entities. It now awaits a floor vote in the House. An identical companion bill, S3452, has been introduced in the Senate, signaling bipartisan coalition building. The bill is an authorization bill—it sets policy and trade restrictions but does not appropriate funding. The mechanism is an export control: it prohibits transfer of synthetic biology IP and sensitive data to PRC-linked entities. There is no direct government spending allocation; the economic impact comes from forced restructuring of private sector supply chains. Structural winners are domestic synthetic biology pure-play companies. Ginkgo Bioworks ($DNA) at $8.07 has rallied 31.48% in the last 30 days, reflecting market anticipation of this shift. Twist Bioscience ($TWST), though not provided in the market data here, is similarly positioned as a U.S.-based DNA synthesis leader. Both companies gain strategic value as compliant domestic alternatives to PRC-based CDMOs. Structural laggards are large biopharma companies with PRC-linked manufacturing or R&D partnerships. Amgen ($AMGN) at $348.89 (30-day -0.84%) and Regeneron ($REGN) at $706.58 (30-day -8.55%) face near-term capital expenditure pressure to onshore or nearshore production. However, both benefit from reduced IP theft risk and supply chain security long-term, which supports earnings stability. Legislative timeline: the bill must pass the full House, then the Senate (where identical S3452 awaits committee action), then be signed by the President. Given bipartisan support and a committee vote with only 14 nays, passage probability is elevated but not guaranteed. Floor action could occur within weeks.